Pharmacokinetics, immunogenicity, and safety of weekly dosing of brentuximab vedotin in pediatric patients with Hodgkin lymphoma

被引：0
|
作者：
Jamie E. Flerlage
Monika L. Metzger
Jianrong Wu
John C. Panetta
机构：
[1] The University of Tennessee Health Science Center,Department of Oncology, St. Jude Children’s Research Hospital
[2] The University of Tennessee Health Science Center,Department of Biostatistics, St. Jude Children’s Research Hospital
[3] The University of Tennessee Health Science Center,Pharmaceutical Sciences, St. Jude Children’s Research Hospital
来源：
Cancer Chemotherapy and Pharmacology | 2016年 / 78卷
关键词：
Brentuximab vedotin; Pharmacokinetics; Pediatric; Hodgkin lymphoma;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1217 / 1223
页数：6
相关论文
共 50 条
  • [21] Desensitization of Brentuximab Vedotin in a Patient with Hodgkin Lymphoma
    Khalid, Sidra
    Khalid, Aariez
    Clark, Bernadette A.
    Daw, Hamed
    CUREUS, 2018, 10 (07):
  • [22] Brentuximab Vedotin in Children with Hodgkin's Lymphoma
    Kazantsev, I.
    Kozlov, A.
    Iukhta, T.
    Gevorgian, A.
    Tolkunova, P.
    Tsvetkova, L.
    Morozova, E.
    Lepik, K.
    Kulagin, A.
    Mikhailova, N.
    Zubarovskaya, L.
    PEDIATRIC BLOOD & CANCER, 2021, 68 : S202 - S202
  • [23] Brentuximab vedotin for the treatment of Hodgkin's lymphoma
    Anh Pham
    Chen, Robert
    EXPERT REVIEW OF HEMATOLOGY, 2015, 8 (04) : 403 - 412
  • [24] Brentuximab vedotin for advanced Hodgkin's lymphoma
    Fanale, Michelle A.
    LANCET ONCOLOGY, 2017, 18 (12): : 1566 - 1568
  • [25] Brentuximab vedotin in combination with bendamustine in pediatric patients or young adults with relapsed or refractory Hodgkin lymphoma
    Vinti, Luciana
    Pagliara, Daria
    Buffardi, Salvatore
    Di Ruscio, Valentina
    Stocchi, Francesca
    Mariggio, Elena
    Parasole, Rosanna
    Di Matteo, Antonia
    Petruzziello, Fara
    Paganelli, Valeria
    De Vito, Rita
    Del Bufalo, Francesca
    Strocchio, Luisa
    Locatelli, Franco
    PEDIATRIC BLOOD & CANCER, 2022, 69 (04)
  • [26] Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin's Lymphoma
    Castellino, Sharon M. M.
    Pei, Qinglin
    Parsons, Susan K. K.
    Hodgson, David
    McCarten, Kathleen
    Horton, Terzah
    Cho, Steve
    Wu, Yue
    Punnett, Angela
    Dave, Hema
    Henderson, Tara O. O.
    Hoppe, Bradford S. S.
    Charpentier, Anne-Marie
    Keller, Frank G. G.
    Kelly, Kara M. M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (18): : 1649 - 1660
  • [27] Where Does Brentuximab Vedotin Fit into the Management of Patients with Hodgkin Lymphoma?
    Goyal, Sagun D.
    Bartlett, Nancy L.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2012, 7 (03) : 179 - 185
  • [28] Where Does Brentuximab Vedotin Fit into the Management of Patients with Hodgkin Lymphoma?
    Sagun D. Goyal
    Nancy L. Bartlett
    Current Hematologic Malignancy Reports, 2012, 7 : 179 - 185
  • [29] Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin
    Zinzani, Pier Luigi
    Derenzini, Enrico
    Pellegrini, Cinzia
    Celli, Monica
    Broccoli, Alessandro
    Argnani, Lisa
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 163 (05) : 681 - 683
  • [30] Frontline Brentuximab Vedotin as Monotherapy or in Combination for Older Hodgkin Lymphoma Patients
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (02) : 9 - 10
12345